Islet perturbations in rats fed a high-fat diet

Pancreas

Volumn 18, Issue 1, 1999, Pages 75-83

  Ahrén, Bo ^a,c   Gudbjartsson, Tomas ^b   Al Amin, Ali Naser ^a   Mårtensson, Hans ^b   Myrsén Axcrona, Ulrika ^a   Karlsson, Sven ^a   Mulder, Hindrik ^a   Sundler, Frank ^a  

^a LUND UNIVERSITY   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Insulin gene expression; Insulin secretion; Neuropeptide Y; Vasoactive intestinal polypeptide

Indexed keywords

GLUCOSE; INSULIN; MESSENGER RNA; NEUROPEPTIDE; NEUROPEPTIDE Y; PROINSULIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FAT INTAKE; FEMALE; GENE EXPRESSION; IN SITU HYBRIDIZATION; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT;

EID: 0032922254     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199901000-00010     Document Type: Article

References (37)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992;15:318-68.
2. Kahn SE, Prigeon RL, McCulloch DSK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993;42:1663-72.
3. Larsson H, Ahrén B. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 1996;39:1099-107.
4. Larsson H, Ahrén B. Islet dysfunction in obese women with impaired glucose tolerance. Metabolism 1996;45:502-9.
5. Porte D Jr. B-cells in type II diabetes mellitus. Diabetes 1991;40: 166-80.
6. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983;173:68-75.
7. Dubuc PU. The development of obesity, hyperinsulinemia and hyperglycemia in ob/ob mice. Metabolism 1976;25:1567-74.
8. Garthwaite TL, Martinson DR, Tseng LF, Hagen TC, Menahan LA. A longitudinal hormonal profile of the genetically obese mouse. Endocrinology 1980;107:671-6.
9. Veroni MC, Proietto J, Larkins RG. Evolution of insulin resistance in New Zealand obese mice. Diabetes 1991;40:1480-7.
10. Mulder H, Ahrén B, Stridsberg M, Sundler F. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 1995; 38:395-402.
11. Grundleger ML, Thenen SW. Decreased insulin binding, glucose transport, and glucose metabolism in soleus muscle of rats fed a high fat diet. Diabetes 1982;31:232-7.
12. Iwanishi M, Kobayashi M. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 1993; 42:1017-21.
13. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 1989;38:1089-93.
14. Kraegen EW, James DE, Storlien LH, Burleigh KM, Chisholm DJ. In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: assessment by euglycemic clamp plus deoxyglucose administration. Diabetologia 1986;29:192-8.
15. Lavau M, Fried SK, Susini C, Freychet P. Mechanism of insulin resistance in adipocytes of rats fed a high-fat diet. J Lipid Res 1979;20:8-16.
16. 14C-Glucose metabolism in vivo in rats rendered obese by a high fat diet. J Lipid Res 1975;16:134-42.
17. Maegawa H, Kobayashi M, Ishibashi O, Takata Y, Shigeta Y. Effect of diet change on insulin action: difference between muscles and adipocytes. Am J Physiol 1986;251:E616-23.
18. Pascoe WS, Storlien LH. Inducement by fat feeding of basal hyperglycemia in rats with abnormal β-cell function: model for study of etiology and pathogenesis of NIDDM. Diabetes 1990;39:226-33.
19. Stevenson RW, McPherson RK, Persson LM, et al. The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Diabetes 1996;45:60-6.
20. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW. Fat feeding causes widespread insulin resistance, decreased energy expenditure and obesity in rats. Am J Physiol 1986;251:E576-83.
21. Watarai T, Kobayashi M, Takata Y, Sasaoka T, Iwasaki M, Shigeta Y. Alteration of insulin-receptor kinase activity by high-fat feeding. Diabetes 1988;37:1397-404.
22. 2+ efflux and insulin secretion from isolated rat islets. Acta Physiol Scand 1988;132:289-96.
23. Mulder H, Ahrén B, Sundler F. Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 1996;39:649-57.
24. Coons AH, Leduc EM, Connolly JM. Studies on antibody production: I. a method for the histochemical determination of specific antibodies and its application to a study of the hyperimmune rat. J Exp Med 1955;102:49-59.
25. Unger RH. How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab 1997;8:276-82.
26. Abdel-Halim SM, Guenifi A, Khan A, et al. Impaired coupling of glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP. Diabetes 1996;45:934-40.
27. Ohneda M, Inman LR, Unger RJ. Caloric restriction in obese prediabetic rats prevents beta-cell depletion, loss of beta cell GLUT 2 and glucose incompetence. Diabetologia 1995;38:173-9.
28. Chan CB, MacPhail RM, Mitton K. Evidence for defective glucose sensing by islets of fa/fa obese Zucker rats. Can J Physiol Pharmacol 1993;71:34-9.
29. de Souza CJ, Yu JH, Robinson DD, Ulrich RG, Meglasson MD. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes 1995;44:984-91.
30. Beloff-Chain A, Newman ME, Mansford KRL. In vitro studies on insulin secretion in the genetically obese mouse. Diabetologia 1973;9:447-52.
31. Ahrén B, Simonsson E, Scheurink AJW, Mulder H, Myrsén U, Sundler F. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 1997;46:97-106.
32. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990;127:1580-9.
33. Boden C. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
34. Edvell A, Lindström P. Development of insulin secretory function in young obese hyperglycemic mice (Umeå ob/ob). Metabolism 1995;44:906-13.
35. Ahrén B, Taborsky GJ Jr, Porte D Jr. Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia 1986;29:827-36.
36. Kohnert KD, Myrsén U, Sundler F, Kloting I, Ahrén B. Reduced islet innervation in type 2 diabetic hamsters. Diabetologia 1997; 40(suppl 1):A133.
37. Szecowka J, Sandberg E, Efendic S. The interaction of vasoactive intestinal polypeptide (VIP), glucose and arginine on the secretion of insulin, glucagon and somatostatin in the perfused rat pancreas. Diabetologia 1980;19:137-42.